Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name (Ascending) Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
63323-0132-15 63323-0132 MITOXANTRONE HYDROCHLORIDE Mitoxantrone 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracenedione Intravenous April 11, 2006 In Use
00703-4680-01 00703-4680 Mitoxantrone Mitoxantrone 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracenedione Intravenous April 11, 2006 In Use
00703-4685-01 00703-4685 Mitoxantrone Mitoxantrone 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracenedione Intravenous April 11, 2006 In Use
00703-4686-01 00703-4686 Mitoxantrone Mitoxantrone 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracenedione Intravenous April 11, 2006 In Use
55390-0083-01 55390-0083 Mitoxantrone Mitoxantrone Chemotherapy Antitumor Antibiotic Anthracenedione Intravenous April 11, 2006 May 31, 2010 No Longer Used
55390-0084-01 55390-0084 Mitoxantrone Mitoxantrone Chemotherapy Antitumor Antibiotic Anthracenedione Intravenous April 11, 2006 May 31, 2010 No Longer Used
55390-0085-01 55390-0085 Mitoxantrone Mitoxantrone Chemotherapy Antitumor Antibiotic Anthracenedione Intravenous April 11, 2006 May 31, 2010 No Longer Used
00069-0080-01 00069-0080 Mitoxantrone Hydrochloride Mitoxantrone Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracenedione Intravenous Dec. 12, 2012 Dec. 31, 2016 No Longer Used
00024-5862-01 00024-5862 Plerixafor Mozobil 24.0 mg/1.2mL Ancillary Therapy Immunostimulant Stem Cell Mobilizer Subcutaneous Sept. 1, 2013 In Use
58468-0140-01 58468-0140 Plerixafor Mozobil 24.0 mg/1.2mL Ancillary Therapy Immunostimulant Stem Cell Mobilizer Subcutaneous Dec. 15, 2008 March 23, 2018 No Longer Used
55292-0911-51 55292-0911 Mechlorethamine hydrochloride Mustargen 10.0 mg/10mL Chemotherapy Alkylating Agent Nitrogen Mustard Intracavitary, Intravenous March 15, 1949 March 31, 2019 No Longer Used
67386-0911-51 67386-0911 Mechlorethamine hydrochloride Mustargen Chemotherapy Alkylating Agent Nitrogen Mustard Intracavitary, Intravenous March 15, 1949 April 15, 2013 No Longer Used
69448-0001-05 69448-0001 Mitomycin Mutamycin 5.0 mg/10mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous July 25, 2017 In Use
69448-0002-11 69448-0002 Mitomycin Mutamycin 20.0 mg/40mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous July 25, 2017 In Use
69448-0003-38 69448-0003 Mitomycin Mutamycin 40.0 mg/80mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous July 25, 2017 In Use
00173-0713-25 00173-0713 Busulfan Myleran Chemotherapy Alkylating Agent Alkylsulfonate Oral March 21, 1985 March 31, 2014 No Longer Used
76388-0713-25 76388-0713 Busulfan Myleran 2.0 mg/1 Chemotherapy Alkylating Agent Alkylsulfonate Oral March 21, 1985 June 30, 2023 No Longer Used
00008-4510-01 00008-4510 Gemtuzumab ozogamicin Mylotarg 5.0 mg/5mL Immunotherapy Drug Antibody Conjugate CD33 Intravenous Sept. 7, 2017 In Use
54868-6366-00 54868-6366 Isotretinoin Myorisan 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Aug. 23, 2012 In Use
54868-6378-00 54868-6378 Isotretinoin Myorisan 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Oct. 29, 2012 In Use
61748-0301-01 61748-0301 Isotretinoin Myorisan 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0301-11 61748-0301 Isotretinoin Myorisan 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0301-13 61748-0301 Isotretinoin Myorisan 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0302-01 61748-0302 Isotretinoin Myorisan 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0302-11 61748-0302 Isotretinoin Myorisan 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0302-13 61748-0302 Isotretinoin Myorisan 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0303-01 61748-0303 Isotretinoin Myorisan 30.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Aug. 26, 2015 In Use
61748-0303-11 61748-0303 Isotretinoin Myorisan 30.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Aug. 26, 2015 In Use
61748-0303-13 61748-0303 Isotretinoin Myorisan 30.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Aug. 26, 2015 In Use
61748-0304-01 61748-0304 Isotretinoin Myorisan 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0304-11 61748-0304 Isotretinoin Myorisan 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0304-13 61748-0304 Isotretinoin Myorisan 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
80978-0111-06 80978-0111 Nelarabine injection NELARABINE 250.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous April 12, 2023 In Use
00069-0324-01 00069-0324 Pegfilgrastim-apgf NYVEPRIA 6.0 mg/.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Dec. 15, 2020 In Use
64370-0532-01 64370-0532 Vinorelbine tartrate Navelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Nov. 15, 2005 Oct. 31, 2021 No Longer Used
64370-0532-02 64370-0532 Vinorelbine tartrate Navelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Nov. 15, 2005 Oct. 31, 2021 No Longer Used
00078-0274-22 00078-0274 Cyclosporine NeOral 100.0 mg/mL Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral July 14, 1995 In Use
55154-3418-00 55154-3418 cyclosporine NeOral 25.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral July 14, 1995 Nov. 30, 2015 No Longer Used
00078-0246-15 00078-0246 Cyclosporine NeOral 25.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral July 14, 1995 In Use
00078-0246-61 00078-0246 Cyclosporine NeOral 25.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral Aug. 13, 2012 In Use
00078-0248-15 00078-0248 cyclosporine NeOral 100.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral July 14, 1995 In Use
00078-0248-61 00078-0248 cyclosporine NeOral 100.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral Aug. 13, 2012 In Use
70771-1685-01 70771-1685 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Nov. 17, 2021 In Use
70771-1685-08 70771-1685 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Nov. 17, 2021 In Use
70710-1726-01 70710-1726 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Nov. 17, 2021 In Use
70710-1726-08 70710-1726 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Nov. 17, 2021 In Use
43598-0142-06 43598-0142 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Jan. 9, 2023 In Use
43598-0142-11 43598-0142 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous March 1, 2023 In Use
70121-1743-04 70121-1743 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous April 10, 2023 In Use
71288-0165-53 71288-0165 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Jan. 10, 2023 In Use
81927-0111-01 81927-0111 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous March 15, 2023 In Use
81927-0111-06 81927-0111 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous March 15, 2023 In Use
70710-1839-01 70710-1839 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous June 24, 2022 In Use
70710-1839-08 70710-1839 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous June 24, 2022 In Use
68083-0233-06 68083-0233 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Jan. 3, 2024 In Use
70437-0240-18 70437-0240 Neratinib Nerlynx 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral July 17, 2017 In Use
70437-0240-26 70437-0240 Neratinib Nerlynx 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral July 17, 2017 In Use
70437-0240-33 70437-0240 Neratinib Nerlynx 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral July 17, 2017 In Use
54868-5229-00 54868-5229 Pegfilgrastim Neulasta Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Feb. 23, 2006 Dec. 31, 2011 No Longer Used
55513-0190-01 55513-0190 Pegfilgrastim Neulasta 6.0 mg/.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous April 1, 2002 In Use
55513-0192-01 55513-0192 Pegfilgrastim Neulasta Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Feb. 20, 2015 In Use
54868-2522-00 54868-2522 Filgrastim Neupogen 300.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous June 8, 1994 In Use
54868-2522-01 54868-2522 Filgrastim Neupogen 300.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous June 8, 1994 In Use
54868-3050-00 54868-3050 Filgrastim Neupogen 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous Aug. 14, 2006 In Use
54868-5020-00 54868-5020 Filgrastim Neupogen 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous March 11, 2004 In Use
55513-0209-01 55513-0209 Filgrastim Neupogen 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
55513-0209-10 55513-0209 Filgrastim Neupogen 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
55513-0209-91 55513-0209 Filgrastim Neupogen 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
55513-0530-01 55513-0530 Filgrastim Neupogen 300.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous May 19, 1997 In Use
55513-0530-10 55513-0530 Filgrastim Neupogen 300.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous May 19, 1997 In Use
55513-0546-01 55513-0546 Filgrastim Neupogen 480.0 ug/1.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous April 7, 1997 In Use
55513-0546-10 55513-0546 Filgrastim Neupogen 480.0 ug/1.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous April 7, 1997 In Use
55513-0924-01 55513-0924 Filgrastim Neupogen 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
55513-0924-10 55513-0924 Filgrastim Neupogen 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
55513-0924-91 55513-0924 Filgrastim Neupogen 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
50419-0488-58 50419-0488 Sorafenib Nexavar 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET, CRAF, BRAF Oral Dec. 20, 2005 In Use
50419-0489-01 50419-0489 Sorafenib Nexavar 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, KIT, RET, RET/PTC, FLT3, CRAF, BRAF Oral Oct. 2, 2023 In Use
00088-1111-14 00088-1111 Nilutamide Nilandron 150.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Sept. 19, 1996 March 31, 2015 No Longer Used
24987-0111-14 24987-0111 Nilutamide Nilandron 150.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 15, 2013 Aug. 31, 2017 No Longer Used
24987-0111-15 24987-0111 Nilutamide Nilandron 150.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Oct. 25, 2013 July 7, 2014 No Longer Used
59212-0111-10 59212-0111 Nilutamide Nilandron 150.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Jan. 1, 2016 Oct. 25, 2018 In Use
59212-0111-14 59212-0111 Nilutamide Nilandron 150.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 15, 2013 In Use
62559-0173-31 62559-0173 Nilutamide Nilutamide 150.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 18, 2016 In Use
66993-0212-38 66993-0212 Nilutamide Nilutamide 150.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Nov. 22, 2019 In Use
82454-0212-03 82454-0212 Nilutamide Nilutamide 150.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Nov. 22, 2019 In Use
63020-0078-01 63020-0078 Ixazomib Ninlaro 2.3 mg/1 Chemotherapy Proteasome Inhibitor 20S Oral Nov. 20, 2015 No Longer Used
63020-0078-02 63020-0078 Ixazomib Ninlaro 2.3 mg/1 Chemotherapy Proteasome Inhibitor 20S Oral Nov. 20, 2015 Oct. 31, 2023 No Longer Used
63020-0079-01 63020-0079 Ixazomib Ninlaro 3.0 mg/1 Chemotherapy Proteasome Inhibitor 20S Oral Nov. 20, 2015 No Longer Used
63020-0079-02 63020-0079 Ixazomib Ninlaro 3.0 mg/1 Chemotherapy Proteasome Inhibitor 20S Oral Nov. 20, 2015 Oct. 31, 2023 No Longer Used
63020-0080-01 63020-0080 Ixazomib Ninlaro 4.0 mg/1 Chemotherapy Proteasome Inhibitor 20S Oral Nov. 20, 2015 Oct. 31, 2023 No Longer Used
63020-0080-02 63020-0080 Ixazomib Ninlaro 4.0 mg/1 Chemotherapy Proteasome Inhibitor 20S Oral Nov. 20, 2015 Oct. 31, 2023 No Longer Used
00409-0801-01 00409-0801 Pentostatin Nipent 2.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 15, 2007 In Use
00409-0801-09 00409-0801 Pentostatin Nipent 2.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 15, 2007 Oct. 1, 2016 In Use
00069-0291-01 00069-0291 filgrastim-aafi Nivestym 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Sept. 24, 2018 In Use
00069-0291-10 00069-0291 filgrastim-aafi Nivestym 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Sept. 24, 2018 In Use
00069-0292-01 00069-0292 filgrastim-aafi Nivestym 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Sept. 24, 2018 In Use
00069-0292-10 00069-0292 filgrastim-aafi Nivestym 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Sept. 24, 2018 In Use
00069-0293-10 00069-0293 filgrastim-aafi Nivestym 300.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous March 11, 2019 In Use
00069-0294-10 00069-0294 filgrastim-aafi Nivestym 480.0 ug/1.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous March 11, 2019 In Use
00310-0600-30 00310-0600 Tamoxifen Citrate Nolvadex Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Dec. 1, 1995 March 31, 2008 No Longer Used

Found 10,000 results in 11 milliseconds — Export these results